Thermo Fisher Scientific Inc. logo

Thermo Fisher Scientific Inc. (TMO)

Market Closed
24 Feb, 20:00
NYSE NYSE
$
515. 60
-0.84
-0.16%
After Hours
$
517. 80
+2.2 +0.43%
191.96B Market Cap
37.17 P/E Ratio
1.56% Div Yield
910,898 Volume
21.53 Eps
$ 516.44
Previous Close
Day Range
513.21 521.63
Year Range
385.46 643.99
Want to track TMO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
TMO earnings report is expected in 56 days (21 Apr 2026)
TMO Stock Gains From Innovation Amid Macroeconomic Issues

TMO Stock Gains From Innovation Amid Macroeconomic Issues

Thermo Fisher's business strategy involves expansion through strategic acquisition of technologies and businesses that boost its existing products and services.

Zacks | 1 year ago
TMO Stock to Gain From Expanded Bioanalytical Services in Sweden

TMO Stock to Gain From Expanded Bioanalytical Services in Sweden

Thermo Fisher's PPD arm unveils a new facility in Sweden, expanding its bioanalytical capabilities.

Zacks | 1 year ago
Thermo Fisher Scientific (TMO) presents at Morgan Stanley 22nd Annual Global Healthcare Conference - Conference Call Transcript

Thermo Fisher Scientific (TMO) presents at Morgan Stanley 22nd Annual Global Healthcare Conference - Conference Call Transcript

Thermo Fisher Scientific (NYSE:TMO ) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 8:30 AM ET Company Participants Marc Casper - Chairman, President and CEO Conference Call Participants Tejas Savant - Morgan Stanley Tejas Savant Hey, everyone. Good morning.

Seekingalpha | 1 year ago
Why Is Thermo Fisher (TMO) Up 1.6% Since Last Earnings Report?

Why Is Thermo Fisher (TMO) Up 1.6% Since Last Earnings Report?

Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 year ago
Reasons to Retain Thermo Fisher (TMO) in Your Portfolio Now

Reasons to Retain Thermo Fisher (TMO) in Your Portfolio Now

Strategic alliances and impressive product launches bode well for Thermo Fisher (TMO).

Zacks | 1 year ago
Thermo Fisher's (TMO) CDx Gets FDA's Nod for Synovial Sarcoma

Thermo Fisher's (TMO) CDx Gets FDA's Nod for Synovial Sarcoma

Thermo Fisher Scientific TMO recently secured FDA's 510(k) clearance for its SeCore CDx HLA A Sequencing System for use as a companion diagnostic (CDx) alongside Adaptimmune's ADAP newly approved T-cell receptor (TCR) therapy, TECELRA (afamitresgene autoleucel). The latter is the first engineered cell therapy for a solid tumor cancer approved in the United States and the first new therapy option in more than a decade for synovial sarcoma — a rare, soft tissue cancer that most commonly impacts young adults.

Zacks | 1 year ago
Thermo Fisher: A Dividend Investor's Lab Partner For Growth And Stability

Thermo Fisher: A Dividend Investor's Lab Partner For Growth And Stability

Thermo Fisher Scientific is a top dividend growth stock with a complex post-pandemic situation. Recent earnings show promising growth in key segments, despite a high valuation. Strategic investments in R&D and acquisitions position TMO for continued long-term success.

Seekingalpha | 1 year ago
3 Nanotechnology Stocks With Microscopic Risk

3 Nanotechnology Stocks With Microscopic Risk

Given the expanding size of the nanotechnology industry, buying nanotechnology stocks with a very low-risk profile is possible. Electronics is one of the most important sectors that applies nanotechnology.

Investorplace | 1 year ago
Thermo Fisher Scientific: Microscopic Signs Of Growth Emerging

Thermo Fisher Scientific: Microscopic Signs Of Growth Emerging

Thermo Fisher Scientific is finally starting to show signs of growth after getting through the headwind of declining covid-related business. Growth sources include increased business in China, completion of the Olink deal, and an increase in the number of clinical trials. Financial model updates and valuation analysis suggest the stock is currently priced at fair value, making it a Hold for now.

Seekingalpha | 1 year ago
Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2024 EPS View

Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2024 EPS View

The year-over-year decline in Thermo Fisher's (TMO) Life Science Solutions and Laboratory Products and Biopharma Services revenues disappoints. However, margins expand in the second quarter.

Zacks | 1 year ago
Thermo Fisher (TMO) Reports Q2 Earnings: What Key Metrics Have to Say

Thermo Fisher (TMO) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for Thermo Fisher (TMO) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks | 1 year ago
Thermo Fisher Q2 Earnings Beat Estimates, Guidance Lifted

Thermo Fisher Q2 Earnings Beat Estimates, Guidance Lifted

Thermo Fisher Scientific (TMO) reported better second-quarter earnings than analysts had expected Wednesday, and also raised its projections for the full fiscal year.

Investopedia | 1 year ago
Loading...
Load More